Archive | Canna~Fangled Abstracts RSS feed for this section

tyfs-doc-fw

Related image


PM 2 site 207

Cannabis-related cognitive impairment: a prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study.

Anticancer Drugs. 2019 Jan;30(1):91-97. doi: 10.1097/CAD.0000000000000685. Bar-Sela G1,2, Tauber D2, Mitnik I1, Sheinman-Yuffe H1, Bishara-Frolova T3, Aharon-Peretz J3,2. Author information Abstract OBJECTIVES: In patients with cancer, the use of medical cannabis has increased significantly during the recent years. There is evidence that cannabis consumption may affect cognitive performance; however, this potential effect has not been […]

PM 2 site 207

Reduced prevalence of alcoholic gastritis in hospitalized individuals who consume cannabis.

Alcohol Clin Exp Res. 2018 Dec 10. doi: 10.1111/acer.13930. [Epub ahead of print] Adejumo AC1,2, Li J3, Akanbi O4, Adejumo KL5, Bukong TN2,3. Author information Abstract BACKGROUND: Alcoholic gastritis, a superficial erosive disease of the stomach, is a common manifestation of risky alcohol use. In contrast, cannabis which is frequently co-used with alcohol suppresses gastric […]

PM 2 site 207

Cannabinoid receptor 2 agonist prevents local and systemic inflammatory bone destruction in rheumatoid arthritis.

J Bone Miner Res. 2018 Dec 3. doi: 10.1002/jbmr.3637. [Epub ahead of print] Zhu M1, Yu B2, Bai J2, Wang X1, Guo X2, Liu Y2, Lin J2, Hu S1, Zhang W3, Tao Y2, Hu C1, Yang H2, Xu Y2, Geng D2. Author information Abstract Cannabinoid receptor 2 (CB2) has been implicated as an important clinical […]

PM 2 site 207

Neuropathic Pain.

Semin Neurol. 2018 Dec;38(6):644-653. doi: 10.1055/s-0038-1673679. Epub 2018 Dec 6. Macone A1, Otis JAD1. Author information Abstract Neuropathic pain management is challenging, and typically requires a multifaceted approach. There are several treatment options, both pharmacologic and nonpharmacologic. Of the available pharmacologic agents, those with the strongest supporting evidence include tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and […]

PM 2 site 207

An Integrated Review of Cannabis and Cannabinoids in Adult Oncologic Pain Management.

Pain Manag Nurs. 2018 Dec 6. pii: S1524-9042(18)30209-1. doi: 10.1016/j.pmn.2018.09.006. [Epub ahead of print] Shin S1, Mitchell C2, Mannion K2, Smolyn J2, Meghani SH2. Author information Abstract OBJECTIVE: The objective of this paper is to review the available literature regarding the use of cannabis and cannabinoids in adult oncologic pain management. DESIGN AND DATA SOURCES: […]

PM 2 site 207

Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: A systematic review and meta-analysis.

J Neurochem. 2018 Dec 6. doi: 10.1111/jnc.14639. [Epub ahead of print] Urbi B1,2, Owusu MA3, Hughes I3, Katz M1, Broadley S1,2, Sabet A1,2. Author information Abstract Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder that results from motor neuron damage. Cannabinoids have been proposed as treatments for ALS due to their anti-excitotoxicity, anti-oxidant, and anti-inflammatory […]

PM 2 site 207

Cannabis for peripheral neuropathy: The good, the bad, and the unknown.

Cleve Clin J Med. 2018 Dec;85(12):943-949. doi: 10.3949/ccjm.85a.17115. Modesto-Lowe V1,2,3, Bojka R2, Alvarado C3. Author information Abstract Cannabis may be an effective alternative or adjunctive treatment for peripheral neuropathy, an often debilitating condition for which standard treatments often provide little relief. Most studies show moderately improved pain from inhaled cannabis use, but adverse effects such as […]

Promising neuroprotective effects of β-caryophyllene against LPS-induced oligodendrocyte toxicity: A mechanistic study.

Biochem Pharmacol. 2018 Dec 5. pii: S0006-2952(18)30500-8. doi: 10.1016/j.bcp.2018.12.001. [Epub ahead of print] Askari VR1, Shafiee-Nick R2. Author information Abstract Myelin loss subsequent to oligodendrocyte death has been reported in a variety of myelin-associated disorders such as multiple sclerosis (MS). Lipopolysaccharide (LPS) has been shown to elicit cellular responses in the central nervous system (CNS) […]

PM 2 site 207

Cannabis-based products for pediatric epilepsy: A systematic review.

Epilepsia. 2018 Dec 4. doi: 10.1111/epi.14608. [Epub ahead of print] Elliott J1,2, DeJean D3, Clifford T1,4, Coyle D1, Potter BK1, Skidmore B5, Alexander C6, Repetski AE6, Shukla V2, McCoy B7,8, Wells GA1,2. Author information Abstract OBJECTIVE: To assess the benefits and harms of cannabis-based products for pediatric epilepsy. METHODS: We identified in this living systematic […]

PM 2 site 207

Cannabinoid 2 receptor attenuates inflammation during skin wound healing by inhibiting M1 macrophages rather than activating M2 macrophages.

J Inflamm (Lond). 2018 Dec 4;15:25. doi: 10.1186/s12950-018-0201-z. eCollection 2018. Du Y1,2,3, Ren P1,2,3, Wang Q4, Jiang SK1,3, Zhang M1,3, Li JY1,3, Wang LL1,3, Guan DW1,3. Author information Abstract BACKGROUND: The anti-inflammatory properties of the cannabinoid 2 receptor (CB2R) in injury and inflammatory diseases have been widely substantiated. Specifically, the anti-inflammatory effect of CB2R may […]